New Insight: A Look at OPT-302/Sozinibercept with Megan Baldwin, PhD
September 8, 202333m 33s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases.
Episode Highlights:
0:06 Introduction
0:37 Background of Dr. Baldwin
9:56 Promising data on OPT-302/sozinibercept
16:39 Making decisions as a clinician, industry leader
22:11 Future of the treatment landscape
28:24 What’s next for Opthea?
32:39 Conclusion
Please direct any podcast-related inquiries to [email protected].
Episode Highlights:
0:06 Introduction
0:37 Background of Dr. Baldwin
9:56 Promising data on OPT-302/sozinibercept
16:39 Making decisions as a clinician, industry leader
22:11 Future of the treatment landscape
28:24 What’s next for Opthea?
32:39 Conclusion
Please direct any podcast-related inquiries to [email protected].